## Re: SPAN: Yale TTC from Pilot and MRI Validation

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 2:01

PN

To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu, Ryan Cabeen |

Ryan.Cabeen@loni.usc.edu
Cc: Jessica Lamb | lambj@usc.edu

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks, Karisma

From: Ayata, Cenk, M.D. | CAYATA@mgh.harvard.edu

Monday, May 17, 2:09 PM

To: Karisma Nagarkatti (USC) | nagarkat@usc.edu

Cc: Ryan Cabeen | Ryan.Cabeen@loni.usc.edu, Jessica Lamb (USC) | lambj@usc.edu

Hi, I see only 2 here.

C

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <a href="https://www.massgeneralbrigham.org/complianceline">www.massgeneralbrigham.org/complianceline</a>. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 5:00 PM

**External Email - Use Caution** 

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks,

Karisma

<YL\_QC2311\_.png><YL\_AM3691.JPG><YL\_AM3691.JPG><TTC volume day 2 Yale site.xlsx> <YL\_Day30\_histo\_30Nov21\_email.pdf><YL\_email\_TTC\_29Sep20.pdf>

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 2:11

РМ

To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu, Ryan Cabeen |

Ryan.Cabeen@loni.usc.edu

Cc: Jessica Lamb | lambj@usc.edu

Here is the third image QC2311

From: Karisma A Nagarkatti To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu | Monday, May 17, 2:00 PM

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks,

Karisma

From: Ayata, Cenk, M.D. | CAYATA@mgh.harvard.edu

Monday, May 17, 2:12 PM

To: Karisma Nagarkatti (USC) | nagarkat@usc.edu

Cc: Ryan Cabeen | Ryan.Cabeen@loni.usc.edu, Jessica Lamb (USC) | lambj@usc.edu

No, I got that, the other two images seem identical?

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <a href="https://www.massgeneralbrigham.org/complianceline">www.massgeneralbrigham.org/complianceline</a>. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 5:11 PM

**External Email - Use Caution** 

Here is the third image QC2311

From: Karisma A Nagarkatti To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu

Monday, May 17, 2:00 PM

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks,

Karisma

<YL\_QC2311\_.png>

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 2:23 PM

To: Ayata, Cenk, M.D. | CAYATA@mgh.harvard.edu

Cc: Ryan Cabeen | Ryan.Cabeen@loni.usc.edu, Jessica Lamb | lambj@usc.edu

Hi Drs. Ayata and Cabeen,

I have re-attached the missing FR8091. Similarly, I am keeping these in the google drive link (please see below). Additionally, you will see the D2 TTC images sent by Augusta last week. I have labeled old folders Pilot2020 and new folders 2021. Let me know if you have any questions.

drive.google.com/drive/folders/1CdTb9FsfQJfGVkgClzaZHIQ25Xwl7NPV?usp=sharing

thanks,

Karisma

From: Ayata | CAYATA@mgh.harvard.edu To: Karisma A Nagarkatti | nagarkat@usc.edu Monday, May 17, 2:12 PM

No, I got that, the other two images seem identical?

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <a href="https://www.massgeneralbrigham.org/complianceline">www.massgeneralbrigham.org/complianceline</a>. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 5:11 PM

**External Email - Use Caution** 

Here is the third image QC2311

From: Karisma A Nagarkatti To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu | N

Monday, May 17, 2:00 PM


Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks,

Karisma



From: Ayata, Cenk, M.D. | CAYATA@mgh.harvard.edu

Monday, May 17, 2:37 PM

To: Karisma Nagarkatti (USC) | nagarkat@usc.edu

Cc: Ryan Cabeen | Ryan.Cabeen@loni.usc.edu, Jessica Lamb (USC) | lambj@usc.edu

What do you think, Ryan, can we make do with these and give Yale a break?

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <a href="https://www.massgeneralbrigham.org/complianceline">www.massgeneralbrigham.org/complianceline</a>. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

From: Karisma A Nagarkatti | nagarkat@usc.edu

Monday, May 17, 5:11 PM

**External Email - Use Caution** 

Here is the third image QC2311

From: Karisma A Nagarkatti To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu

Monday, May 17, 2:00 PM

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks,

Karisma

<YL\_QC2311\_.png>

From: Ryan Cabeen | ryan.cabeen@loni.usc.edu

To: Karisma Nagarkatti (USC) | nagarkat@usc.edu, Ayata, Cenk, M.D. |

CAYATA@mgh.harvard.edu

Cc: Jessica Lamb (USC) | lambj@usc.edu

Yes, I think these will be quite useful!

My only thought is to have higher resolution photographs, since they are somewhat grainy when zoomed into individual sections. Maybe that's not necessary for judging lesion boundaries though, unless you think there are other finer details that might be important.

Ryan P. Cabeen, PhD
Chan Zuckerberg Imaging Scientist
Assistant Professor of Research Neurology
Laboratory of Neuro Imaging
USC Stevens Neuroimaging and Informatics Institute
Keck School of Medicine of USC
University of Southern California
2025 Zonal Ave.

Los Angeles, CA 90033

Tel: (323) 44-BRAIN

Email: rcabeen@loni.usc.edu

Web: <u>cabeen.io</u> www.ini.usc.edu

From: CAYATA@mgh.harvard.edu

Monday, May 17, 2:37 PM

What do you think, Ryan, can we make do with these and give Yale a break?

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <a href="https://www.massgeneralbrigham.org/complianceline">www.massgeneralbrigham.org/complianceline</a>. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

From: Karisma A Nagarkatti I nagarkat@usc.edu

Monday, May 17, 5:11 PM

**External Email - Use Caution** 

Here is the third image QC2311

From: Karisma A Nagarkatti To: cayata@mgh.harvard.edu | cayata@mgh.harvard.edu | Monday, May 17, 2:00 PM

Hi Drs. Ayata and Cabeen,

At the Weekly Stage 2 Meeting Dr. Boisserand had inquired about whether Yale would need to submit more D2 TTC images. As you may recall the site had sent in 3 D2 images for the Stage 1 Pilot in 2020.

I have re-attached the 3 TTC image files sent by Yale for your review. Please let me know how you would like for Yale to proceed, specifically if Yale will need to submit more images or if these images will suffice for the current MRI validation.

Thanks, Karisma <YL\_QC2311\_.png>